Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) Latest Company News

Oct 23, 2026, 12:30 UTC
The U.S. Food and Drug Administration approved a clinical trial of Ailisi’s AST1001 injection for adults with locally advanced or metastatic solid tumors whose disease failed standard treatment; the IND number is 183542.
Source:
- finance.sina.cn
Oct 13, 2026, 10:54 UTC
Shanghai Allist Pharmaceuticals announced plans to repurchase its shares through centralized bidding using its own funds, for a total of RMB 100 million to RMB 200 million and at no more than RMB 150 per share.
Source:
- finance.sina.cn
Oct 8, 2026, 07:49 UTC
Shanghai Allist Pharmaceuticals reported that its ArriVent equity stake had a carrying value of about 302 million yuan as of June 30, 2026, up 67.31% from the end of 2025.
Source:
- finance.sina.cn
Oct 7, 2026, 08:29 UTC
Shanghai Allist Pharmaceuticals announced that its furmonertinib monotherapy failed to meet the primary endpoint in the FURVENT Phase III trial for first-line treatment of EGFR exon 20 insertion NSCLC.
Source:
- finance.sina.cn
Oct 7, 2026, 08:24 UTC
Shanghai Allist Pharmaceuticals’ controlling shareholder, chairman and general manager Du Jinhao proposed that the company repurchase A-shares using its own funds, with a total amount of RMB 100 million to RMB 200 million, for an employee stock ownership plan or equity incentives.
Source:
- finance.sina.cn
- finance.sina.cn
Sep 21, 2026, 09:56 UTC
Shanghai Allist Pharmaceuticals received acceptance from China's National Medical Products Administration for its marketing application for a new indication of furmonertinib mesylate tablets as adjuvant treatment after tumor resection in adults with EGFR exon 19 deletion or exon 21 (L858R) substitution mutation non-small cell lung cancer.
Source:
- finance.sina.cn
Aug 19, 2026, 08:39 UTC
Ailisi announced a cash dividend of 6.00 yuan per 10 shares, totaling 270 million yuan, for the first half of 2026.
Source:
- finance.sina.cn
- finance.ifeng.com
Aug 18, 2026, 19:54 UTC
Allist Pharmaceuticals forecast first-half 2026 revenue of 3.31 billion yuan and net profit of 1.54 billion yuan, up 39.44% and 46.49% year-on-year respectively, driven by furmonertinib sales.
Source:
- wap.eastmoney.com
- finance.ifeng.com
Aug 18, 2026, 04:14 UTC
Xiangya Second Hospital suspended procurement and use of Allist's furmonertinib mesylate tablets and three other drugs for three months starting August 17, 2026, due to unauthorized visits by pharmaceutical representatives.
Source:
- finance.sina.cn

688578.SH

The U.S. Food and Drug Administration approved a clinical trial of Ailisi’s AST1001 injection for adults with locally advanced or metastatic solid tumors whose disease failed standard treatment; the IND number is 183542.

Shanghai Allist Pharmaceuticals announced plans to repurchase its shares through centralized bidding using its own funds, for a total of RMB 100 million to RMB 200 million and at no more than RMB 150 per share.

Shanghai Allist Pharmaceuticals reported that its ArriVent equity stake had a carrying value of about 302 million yuan as of June 30, 2026, up 67.31% from the end of 2025.

Shanghai Allist Pharmaceuticals announced that its furmonertinib monotherapy failed to meet the primary endpoint in the FURVENT Phase III trial for first-line treatment of EGFR exon 20 insertion NSCLC.

Shanghai Allist Pharmaceuticals’ controlling shareholder, chairman and general manager Du Jinhao proposed that the company repurchase A-shares using its own funds, with a total amount of RMB 100 million to RMB 200 million, for an employee stock ownership plan or equity incentives.

Ailisi announced a cash dividend of 6.00 yuan per 10 shares, totaling 270 million yuan, for the first half of 2026.

Allist Pharmaceuticals forecast first-half 2026 revenue of 3.31 billion yuan and net profit of 1.54 billion yuan, up 39.44% and 46.49% year-on-year respectively, driven by furmonertinib sales.

Xiangya Second Hospital suspended procurement and use of Allist's furmonertinib mesylate tablets and three other drugs for three months starting August 17, 2026, due to unauthorized visits by pharmaceutical representatives.